HC Wainwright & Co. Reiterates Buy on Cogent Biosciences, Maintains $19 Price Target

Benzinga · 05/13 10:34
HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a Buy and maintains $19 price target.